[177Lu]Lu-DOTA-RM26

N/A

Report date: 2025/11/24 17:31:50

Base Information

Drug Name[177Lu]Lu-DOTA-RM26

Drug Alias Name[177 Lu]Lu-DOTA-RM26[177Lu]Lu-DOTA-RM26177Lu-DOTA-RM26

ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agent +[4]

Mechanisms of ActionCalcitonin gene-related peptide receptor antagonists

TargetsCalcitonin gene-related peptide receptor

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryDenmark

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Southern Denmark

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Southern Denmark

Inactive CompaniesN/A

Active IndicationsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A